Login to Your Account

Phase III Avastin/Tarceva Trial Hits Goal in NSCLC Maintenance

By Trista Morrison

Wednesday, February 4, 2009
A Phase III trial evaluating the combination of VEGF-inhibitor Avastin (bevacizumab) and EGFR-inhibitor Tarceva (erlotinib) as a maintenance regimen for non-small-cell lung cancer was stopped early when a preplanned interim analysis demonstrated a significant improvement in progression-free survival, the primary endpoint of the study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription